Newsfeeds - Spark Newswire

1 minute read

Why Xenon Pharmaceuticals Stock Is Soaring Today

October 4, 10:07 AM

Xenon Pharmaceuticals Inc (NASDAQ: XENE) is trading significantly higher Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints.

XENE

3 minute read

Xenon Pharmaceuticals Announces Topline Results From Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 For The Treatment Of Focal Epilepsy; Co. Reports ‘All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups’

By Benzinga Newsdesk

October 4, 7:09 AM

Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and

XENE

1 minute read

News

Xenon Pharmaceuticals On Sunday Announced The Co. Will Have A Conference Call And Webcast To Discuss Topline Results From Phase 2b ‘X-TOLE’ Clinical Trial Of XEN1101

By Benzinga Newsdesk

October 4, 6:57 AM

Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b

XENE

5 minute read

The Daily Biotech Pulse: FDA Rejects FibroGen’s Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering

By Shanthi Rexaline

August 11, 8:14 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)

ACAD

11 minute read

Earnings Scheduled For August 11, 2021

By Benzinga Insights

August 11, 4:27 AM

Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter.

ACVA

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

By Shanthi Rexaline

August 8, 10:03 AM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL

2 minute read

18 Key Biopharma Catalysts To Keep An Eye On In Q3

By Shanthi Rexaline

July 10, 8:03 AM

Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Needham analyst Serge Belanger highlighted companies in the firm's coverage universe that have key catalysts in the third quarter.

ACER

2 minute read

FDA
News

Xenon Pharmaceuticals Announces Completion Of Patient Randomization In XEN1101 Phase 2b ‘X-TOLE’ Clinical Trial, Announces Upcoming Investor Webinar

By Benzinga Newsdesk

July 7, 8:37 AM

Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today provided an update on its ongoing XEN1101 Phase 2b "X-TOLE" clinical trial, announcing that randomization of 326

XENE

1 minute read

News

Looking Into Xenon Pharmaceuticals’s Return On Capital Employed

By Benzinga Insights

June 4, 10:49 AM

During Q1, Xenon Pharmaceuticals's (NASDAQ:XENE) reported sales totaled $4.36 million. Despite a 24.27% in earnings, the company posted a loss of $16.06 million. In Q4, Xenon Pharmaceuticals brought in $5.15 million in sales but lost $12.92 million in earnings.

XENE

9 minute read

Uncategorized

Earnings Scheduled For May 11, 2021

By Benzinga Insights

May 11, 4:13 AM

Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter.

ABST